Announcements Trials

Browse Landscape

Status

Recruiting 1 Not yet recruiting 1 Completed 1

Sponsor Class

Study Type

Observational 1

Sponsor

Cancer Type

Conditions

Carcinoma, Non-Small-Cell Lung 2 Thyroid Neoplasms 1 Neoplasm Metastasis 1 Lung Neoplasms 1 Locally Advanced Thyroid Gland Carcinoma 1 Advanced Thyroid Cancer Patients Who Received Target Therapy 1

Interventions

Magnetic Resonance Spectroscopy 4 Surgical Procedures, Operative 3 Iodine-131 3 Iodine-124 3 Biopsy 3 selpercatinib 2 lenvatinib 2 Watchful Waiting 2 Thyrotropin Alfa 2 Therapeutics 2 Nivolumab 2 Fluorodeoxyglucose F18 2 Cyclophosphamide 2 Cetuximab 2 Biopsy, Fine-Needle 2 trastuzumab deruxtecan 1 trametinib 1 sintilimab 1 sacituzumab govitecan 1 repotrectinib 1 pralsetinib 1 pembrolizumab 1 gallium Ga 68 dotatate 1 fludarabine phosphate 1 defactinib 1 dabrafenib 1 cemiplimab 1 brodalumab 1 binimetinib 1 anlotinib 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Recruiting × Thyroid Neoplasms × pralsetinib × Clear all

NCT07419932 2026-02-19

NeoLATC

Fujian Medical University

Thyroid Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡